MiMedx® Selects Allen & Caron for Investor Relations, Media Relations and Corporate Communications

KENNESAW, Ga., April 30, 2012 /PRNewswire/ -- MiMedx Group, Inc. (OTCBB:MDXG), an integrated developer, manufacturer and marketer of patent protected regenerative biomaterials and bioimplants processed from human amniotic membrane, announced today that it has selected Allen & Caron Inc., with offices in New York City, Irvine CA and London, as its agency for investor relations and corporate communications. Allen & Caron will develop an outreach program to increase visibility in the investment community and business/financial media.

MiMedx Chairman and CEO Parker H. "Pete" Petit commented, "We believe that the rapid increase in physicians utilizing the product dictates that MiMedx Group should be properly introduced to institutional investors both domestically and abroad.  We believe that 2012 will continue to demonstrate very rapid revenue growth as we announce significant clinical results, including randomized controlled trials, and additional reimbursement successes for private pay as well as Medicare.   Our unique amniotic membrane allografts are proving to be a very cost effective and clinically effective addition to many medical procedures.

Mr. Petit said, "We selected Allen & Caron because of their premier reputation and experience with rapidly growing healthcare firms.  We interviewed a number of investor relations firms prior to making our selection.  I am certain they will become an excellent partner in helping us add institutional investors to our existing investor base of high net worth individuals."

Allen & Caron Chairman and CEO Joseph Allen said, "Innovative healthcare companies with strong doctor and patient benefits are one of the best kinds of companies to work with in our business.  When they win, everybody wins.  MiMedx is a perfect example of that type of company.  Their EpiFix® and AmnioFix® products address a broad range of uses that comprise wound care, burn healing, soft tissue trauma, nerve and tendon repair, spinal applications and sports medicine.  We believe that as these products find their audiences the rate of growth at MiMedx will continue to accelerate – although the revenue growth rate is already very high indeed."

About MiMedx Group
MiMedx® is an integrated developer, manufacturer and marketer of patent protected regenerative biomaterial products and bioimplants processed from human amniotic membrane. "Innovations in Regenerative Biomaterials" is the framework behind our mission to give physicians products and tissues to help the body heal itself. Our biomaterial platform technologies include the device technologies HydroFix® and CollaFix™, and our tissue technologies, AmnioFix® and EpiFix®. Our tissue technologies, processed from the human amniotic membrane, utilize our proprietary Purion® Process that was developed by our wholly-owned subsidiary, Surgical Biologics, to produce a safe, effective and minimally manipulated implant for homologous use. Surgical Biologics is the leading supplier of amniotic tissue, having supplied over 70,000 implants to date to distributors and OEMs for application in the Ophthalmic, Orthopedics, Spine, Wound Care and Dental sectors of healthcare.

For more information, visit the company's website at www.mimedx.com.

About Allen & Caron
Allen & Caron is a full-service corporate, investor and marketing communications agency serving the needs of public companies. The Allen & Caron international client base includes emerging growth companies in a broad range of industry segments. The firm has offices in Irvine, California; New York City and London; and has an affiliate relationship with a leading investor relations firm in Italy, which has offices in Milan and Rome.

For more information, visit www.allencaron.com.

Information:
MiMedx: Michael Senken 678-384-6720
Investors: Michael Mason, Allen & Caron 212-691-8087, [email protected]

Safe Harbor Statement
This press release includes statements that look forward in time or that express management's beliefs, expectations or hopes.  Such statements are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.  These statements include, but are not limited to, the the Company's expected revenue growth in 2012, the prospective announcement of significant clinical results;  anticipated growth in demand for the Company's tissue offerings; the impact of the cost and clinical effectiveness of the Company's amniotic membrane allografts on their additional uses in medical procedures; the market opportunities in wound care, burn healing, soft tissue trauma, nerve and tendon repair, spinal applications and sports medicine; the reimbursement prospects of the Company's offerings; and the potential applications for the Company's tissue allografts. These statements are based on current information and belief, and are not guarantees of future performance.  Among the risks and uncertainties that could cause actual results to differ materially from those indicated by such forward-looking statements include that the Company's revenue growth in 2012 does not occur as expected; the results of clinical trials are not as anticipated;  that the anticipated demand for the Company's tissue offerings does not materialize as expected, that the anticipated cost and clinical effectiveness of the Company's allografts does not materialize; that reimbursement for the Company's products is low or that a significant number of payors do not reimburse at all, that the numerous medical applications for the Company's tissue offerings do not materialize, that the Company's products and services may not gain the anticipated acceptance in the marketplace or acceptance may be delayed, and the risk factors detailed from time to time in the Company's periodic Securities and Exchange Commission filings, including, without limitation, its 10-K filing for the fiscal year ended December 31, 2011. By making these forward-looking statements, the Company does not undertake to update them in any manner except as may be required by the Company's disclosure obligations in filings it makes with the Securities and Exchange Commission under the federal securities laws. 

SOURCE MiMedx Group, Inc.